(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 12.19% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.
Pacific Biosciences Of California's revenue in 2026 is $160,030,000.On average, 10 Wall Street analysts forecast PACB's revenue for 2026 to be $54,926,802,506, with the lowest PACB revenue forecast at $51,137,461,912, and the highest PACB revenue forecast at $57,399,191,942. On average, 10 Wall Street analysts forecast PACB's revenue for 2027 to be $61,961,930,739, with the lowest PACB revenue forecast at $57,834,034,306, and the highest PACB revenue forecast at $65,226,354,480.
In 2028, PACB is forecast to generate $70,416,508,686 in revenue, with the lowest revenue forecast at $62,977,598,259 and the highest revenue forecast at $77,196,943,536.